{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:17:46Z","timestamp":1757618266700,"version":"3.44.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["30768"],"award-info":[{"award-number":["30768"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06457-0","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:37:55Z","timestamp":1750293475000},"page":"3869-3873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome"],"prefix":"10.1007","volume":"104","author":[{"given":"Valeria","family":"Cardinali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Coiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paola","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"18","key":"6457_CR1","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","volume":"129","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Yu L, Glynn RJ et al (2017) Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood 129(18):2581\u20132584. https:\/\/doi.org\/10.1182\/blood-2016-10-742437","journal-title":"Blood"},{"issue":"20","key":"6457_CR2","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/blood.2022016953","volume":"140","author":"SA Bhat","year":"2022","unstructured":"Bhat SA, Gambril J, Azali L et al (2022) Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood 140(20):2142\u20132145. https:\/\/doi.org\/10.1182\/blood.2022016953","journal-title":"Blood"},{"issue":"10","key":"6457_CR3","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1182\/bloodadvances.2023011641","volume":"8","author":"JJ Moslehi","year":"2024","unstructured":"Moslehi JJ, Furman RR, Tam CS et al (2024) Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. Blood Adv 8(10):2478\u20132490. https:\/\/doi.org\/10.1182\/bloodadvances.2023011641","journal-title":"Blood Adv"},{"issue":"4","key":"6457_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J et al (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 374(4):311\u2013322","journal-title":"N Engl J Med"},{"key":"6457_CR5","unstructured":"Genentech, Inc. Gazyva\u00ae (obinutuzumab) infusion-related reactions: guide for healthcare professionals. Available from:\u00a0https:\/\/www.gazyva-hcp.com\/content\/dam\/gene\/gazyva-hcp\/global\/pdfs\/GAZYVA-IRR-Guide.pdf"},{"key":"6457_CR6","doi-asserted-by":"crossref","unstructured":"Antzelevitch C, Brugada P, Brugada J et al (2005) Brugada syndrome: report of the second consensus conference: endorsed by the heart rhythm society and the European heart rhythm association. Circulation 111(5):659\u2013670","DOI":"10.1161\/01.CIR.0000152479.54298.51"},{"issue":"6","key":"6457_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/CIRCGENETICS.109.853374","volume":"2","author":"V Probst","year":"2009","unstructured":"Probst V, Wilde AA, Barc J et al (2009) SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet 2(6):552\u2013557. https:\/\/doi.org\/10.1161\/CIRCGENETICS.109.853374","journal-title":"Circ Cardiovasc Genet"},{"issue":"11","key":"6457_CR8","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/cancers16112049","volume":"16","author":"I Del Giudice","year":"2024","unstructured":"Del Giudice I, Della Starza I, De Falco F, Gaidano G, Sportoletti P (2024) Monitoring response and resistance to treatment in chronic lymphocytic leukemia. Cancers (Basel) 16(11):2049 Published 2024 May 28. https:\/\/doi.org\/10.3390\/cancers16112049","journal-title":"Cancers (Basel)"},{"issue":"9","key":"6457_CR9","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M et al (2020) Venetoclax plus obinutuzumab versus Chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 21(9):1188\u20131200. https:\/\/doi.org\/10.1016\/S1470-2045(20)30443-5","journal-title":"Lancet Oncol"},{"issue":"24","key":"6457_CR10","first-page":"2807","volume":"35","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O\u2019Brien S (2017) Cardiovascular toxicity of novel targeted therapies for hematologic malignancies. J Clin Oncol 35(24):2807\u20132815","journal-title":"J Clin Oncol"},{"issue":"12","key":"6457_CR11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann CU, Munir T, Moreno C et al (2023) Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24(12):1423\u20131433. https:\/\/doi.org\/10.1016\/S1470-2045(23)00452-7","journal-title":"Lancet Oncol"},{"key":"6457_CR12","doi-asserted-by":"publisher","unstructured":"AlAsmari AF, Alghamdi A, Ali N et al (2022) Venetoclax induces cardiotoxicity through modulation of oxidative-stress-mediated cardiac inflammation and apoptosis via NF-\u03baB and BCL-2 pathway. Int J Mol Sci 23(11):6260. Published 2022 Jun 2. https:\/\/doi.org\/10.3390\/ijms23116260","DOI":"10.3390\/ijms23116260"},{"issue":"40","key":"6457_CR13","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M et al (2022) 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 43(40):3997\u20134126. https:\/\/doi.org\/10.1093\/eurheartj\/ehac262","journal-title":"Eur Heart J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06457-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06457-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06457-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:38:17Z","timestamp":1757191097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06457-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6457"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06457-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that informed consent to publish information and images was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient publication consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}